title: Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer.
abstract: Identification of biomarkers used for the prognostic evaluation of non-small cell lung cancer (NSCLC) patients is important. The aim of this study was to evaluate the potential prognostic value of XRCC1, ERCC1, ERCC2, and TP53 single nucleotide polymorphisms (SNPs) in completely resected NSCLC patients. In total, 130 patients, surgically treated for NSCLC between 2000 and 2012, were included. An analysis of SNPs from peripheral blood cells was performed by polymerase chain reaction. XRCC1 Arg399Gln, ERCC1 Asn118Asn, ERCC2 Lys751Gln, and TP53 Arg72Pro polymorphisms were evaluated in conjunction with clinical and pathological parameters and survival. Kaplan-Meier method and Cox regression analysis were used. Median age rate was 59.3, ranging between 36 and 78 years. Median relapse-free survival duration (RFS) was found as 46.2 months. In those with ERCC2 CC allele, median RFS was detected as 28.3 months (95 % confidence interval (CI), 20.8-35.8), 46.9 months in those with CT heterozygous (95 % CI, 18.6-75.2), and 80.1 months for those with TT mutant allel (95 % CI, 33.0-127.2). Median RFS was seen to be longer in mutant group and also statistically significant (P = 0.018). Additionally, upon evaluating CC normal group with CT + TT alleles including mutant alleles, median RFS was found as 56.5 months (95 % CI, 24.6-88.4) in CT + TT group, and this was statistically significant (P = 0.005) Also, median RFS was 15.1 months in those including ERCC2 CC allele and 56.5 months in CT + TT allele in the group with no adjuvant treatment (P = 0.001). In conclusion, our study showed that ERCC2/XPD polymorphism is an independent prognostic factor in operated NSCLC patients, and these findings should be supported with prospective studies.
authors.affiliation: Department of Medical Oncology, Meram Medical Faculty, Necmettin Erbakan University, Meram, 42100, Konya, Turkey, caglayange@hotmail.com.
authors.forename: Caglayan
authors.initials: C
authors.lastname: Geredeli
authors.forename: Mehmet
authors.initials: M
authors.lastname: Artac
authors.forename: Selman
authors.initials: S
authors.lastname: Yildirim
authors.forename: Ali
authors.initials: A
authors.lastname: Inal
authors.forename: Isa
authors.initials: I
authors.lastname: Dede
authors.forename: Tunc
authors.initials: T
authors.lastname: Guler
authors.forename: Melih Cem
authors.initials: MC
authors.lastname: Boruban
authors.forename: Lokman
authors.initials: L
authors.lastname: Koral
authors.forename: Mustafa
authors.initials: M
authors.lastname: Karaagac
authors.forename: Ayse Gul
authors.initials: AG
authors.lastname: Zamani
authors.forename: Tamer
authors.initials: T
authors.lastname: Altinok
authors.forename: Olgun
authors.initials: O
authors.lastname: Aribas
authors.forename: Hakan
authors.initials: H
authors.lastname: Bozcuk
authors.forename: Ahmet
authors.initials: A
authors.lastname: Demirkazik
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D004268:DNA-Binding Proteins / Q000235:genetics*; D018572:Disease-Free Survival; D004720:Endonucleases / Q000235:genetics*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D009367:Neoplasm Staging; D010984:Platinum / Q000008:administration & dosage; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*; D000076105:X-ray Repair Cross Complementing Protein 1; D051759:Xeroderma Pigmentosum Group D Protein / Q000235:genetics*
chemical_list: D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D000076105:X-ray Repair Cross Complementing Protein 1; C000619371:XRCC1 protein, human; D010984:Platinum; C071447:ERCC1 protein, human; D004720:Endonucleases; D051759:Xeroderma Pigmentosum Group D Protein; C497292:ERCC2 protein, human